Published in Invest New Drugs on November 01, 2006
On the origin of cancer cells. Science (1956) 49.55
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (1996) 10.14
Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med (1997) 6.86
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol (1991) 5.61
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature (1998) 4.03
Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med (2000) 3.72
Angiogenesis: regulators and clinical applications. Biochem Pharmacol (2001) 2.47
Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Res (1995) 2.24
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today (2000) 1.86
Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res (1996) 1.86
Clinical importance of the determination of tumor angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol (1995) 1.81
Tumor hypoxia: a target for selective cancer therapy. Cancer Sci (2003) 1.49
Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer (2002) 1.27
Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (review). Int J Oncol (2001) 1.18
Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res (1998) 1.16
Synthesis and structure-activity relationship of 2-aminobenzophenone derivatives as antimitotic agents. J Med Chem (2002) 1.06
Cytotoxic benzophenone derivatives from Garcinia species display a strong apoptosis-inducing effect against human leukemia cell lines. Biol Pharm Bull (2003) 1.05
Polyprenylated benzophenones from Garcinia assigu and their potential cancer chemopreventive activities. J Nat Prod (2003) 1.05
Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats. Carcinogenesis (2000) 0.98
Oxygen dependent regulation of DNA synthesis and growth of Ehrlich ascites tumor cells in vitro and in vivo. Cancer Res (1988) 0.96
Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. Bioorg Med Chem (2005) 0.95
Selective and synchronous activation of early-S-phase replicons of Ehrlich ascites cells. Mol Cell Biol (1993) 0.91
Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol (2004) 0.82
VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J Interferon Cytokine Res (2000) 0.81
Structure-activity and crystallographic analysis of benzophenone derivatives-the potential anticancer agents. Bioorg Med Chem Lett (2003) 0.81
Synthesis and antitumor activity of novel benzophenone derivatives. Chem Pharm Bull (Tokyo) (1997) 0.79
Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Anticancer Res (2000) 0.78
Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation? Oncogene (1998) 0.77
Benzophenones as xanthine oxidase inhibitors. Anticancer Res (1999) 0.75
Molecular mechanisms of anti-angiogenic effect of curcumin. Biochem Biophys Res Commun (2002) 1.23
Angiogenic and proliferative effects of the cytokine VEGF in Ehrlich ascites tumor cells is inhibited by Glycyrrhiza glabra. Int Immunopharmacol (2005) 1.04
Crosstalk between VEGF and MTA1 signaling pathways contribute to aggressiveness of breast carcinoma. Mol Carcinog (2013) 0.95
Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. Bioorg Med Chem (2005) 0.95
Antiangiogenic and antiproliferative effects of substituted-1,3,4-oxadiazole derivatives is mediated by down regulation of VEGF and inhibition of translocation of HIF-1alpha in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol (2009) 0.92
Octacosanol isolated from Tinospora cordifolia downregulates VEGF gene expression by inhibiting nuclear translocation of NF-<kappa>B and its DNA binding activity. Eur J Pharmacol (2008) 0.90
Platelet-derived growth factor receptor signaling is not involved in osteogenic differentiation of human mesenchymal stem cells. Tissue Eng Part A (2010) 0.89
N-Substituted-2-butyl-5-chloro-3H-imidazole-4-carbaldehyde derivatives as anti-tumor agents against Ehrlich ascites tumor cells in vivo. Med Chem (2007) 0.86
Pro-apoptotic activity of imidazole derivatives mediated by up-regulation of Bax and activation of CAD in Ehrlich Ascites Tumor cells. Invest New Drugs (2007) 0.86
Antiangiogenic effects of butyric acid involve inhibition of VEGF/KDR gene expression and endothelial cell proliferation. Mol Cell Biochem (2003) 0.85
Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by a new series of substituted-1,3,4-oxadiazole derivatives. Invest New Drugs (2008) 0.85
Evaluation of serum vascular endothelial growth factor (VEGF) and microvessel density (MVD) as prognostic indicators in carcinoma breast. J Cancer Res Clin Oncol (2008) 0.84
Mechanism of inhibition of ascites tumor growth in mice by curcumin is mediated by NF-kB and caspase activated DNase. Mol Cell Biochem (2005) 0.83
Crosstalk between VEGF and novel angiogenic protein regulates tumor angiogenesis and contributes to aggressiveness of breast carcinoma. Cell Signal (2012) 0.82
Synthesis and crystallographic analysis of benzophenone derivatives--the potential anti-inflammatory agents. Bioorg Med Chem (2007) 0.82
Anti-metastatic action of anacardic acid targets VEGF-induced signalling pathways in epithelial to mesenchymal transition. Drug Discov Ther (2015) 0.82
Butyrate-induced proapoptotic and antiangiogenic pathways in EAT cells require activation of CAD and downregulation of VEGF. Biochem Biophys Res Commun (2005) 0.80
Antibacterial activity of synthetic precursors of podophyllotoxin. Int J Biomed Sci (2007) 0.80
Paracrine action of sFLT-1 secreted by stably-transfected Ehrlich ascites tumor cells and therapy using sFLT-1 inhibits ascites tumor growth in vivo. J Gene Med (2009) 0.78
A pro-apoptotic 15-kDa protein from Bacopa monnieri activates caspase-3 and downregulates Bcl-2 gene expression in mouse mammary carcinoma cells. J Nat Med (2012) 0.78
Antiangiogenic and proapoptotic activities of allyl isothiocyanate inhibit ascites tumor growth in vivo. Integr Cancer Ther (2009) 0.78
Synthesis, xanthine oxidase inhibition, and antioxidant screening of benzophenone tagged thiazolidinone analogs. Arch Pharm (Weinheim) (2014) 0.78
Antiangiogenic and proapoptotic activity of a novel glycoprotein from U. indica is mediated by NF-kappaB and Caspase activated DNase in ascites tumor model. Biochimie (2005) 0.77
Design, synthesis, and anticancer properties of novel benzophenone-conjugated coumarin analogs. Arch Pharm (Weinheim) (2013) 0.76
Angiopoietin-2 inhibition using siRNA or the peptide antagonist L1-10 results in antitumor activity in human neuroblastoma. J Cancer Res Clin Oncol (2012) 0.76
Purification and characterization of butyrate-induced protein phosphatase involved in apoptosis of Ehrlich ascites tumor cells. Biochim Biophys Acta (2006) 0.76
Ethyl 2-(4-benzoyl-2,5-dimethyl-phen-oxy)acetate. Acta Crystallogr Sect E Struct Rep Online (2009) 0.75
2-Benzoyl-4-chloro-phenyl benzoate. Acta Crystallogr Sect E Struct Rep Online (2013) 0.75
Ethyl 2-[4-(2-chloro-benzo-yl)-2,6-di-methyl-phen-oxy]ethano-ate. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
Ethyl 2-cyano-5-oxo-5-(thio-phen-2-yl)-3-(3,4,5-trimeth-oxy-phen-yl)penta-noate. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
2,6-Dichloro-phen-yl 4-chloro-benzoate. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
2-Methylxanthen-9-one. Acta Crystallogr Sect E Struct Rep Online (2012) 0.75
4-Chloro-2-(2-chloro-benzoyl)phenol. Acta Crystallogr Sect E Struct Rep Online (2013) 0.75
Inhibition of ascites tumor growth in vivo by sTie-2 is potentiated by a combinatorial therapy with sFLT-1. J Gene Med (2010) 0.75
Synthesis of pyrimidones and evaluation of their xanthine oxidase inhibitory and antioxidant activities. Arch Pharm (Weinheim) (2013) 0.75
WITHDRAWN: Anti-tumor and proapoptotic effect of withaferin A is mediated by up-regulation of Bax and inhibition NF-kappaB in Ehrlich ascites tumor cells. Biochim Biophys Acta (2008) 0.75
Synthesis, antioxidant, and xanthine oxidase inhibitory activities of 5-[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione derivatives. Arch Pharm (Weinheim) (2013) 0.75
Synthesis and evaluation of in vitro antioxidant properties of novel 2,5-disubstituted 1,3,4-oxadiazoles. Bioorg Khim (2015) 0.75
Isolation and characterization of a 29-kDa glycoprotein with antifungal activity from bulbs of Urginea indica. Biochem Biophys Res Commun (2003) 0.75
Buffalo colostrum β-lactoglobulin inhibits VEGF-induced angiogenesis by interacting with G protein-coupled receptor kinase. Appl Biochem Biotechnol (2013) 0.75
Synthesis, angiopreventive activity, and in vivo tumor inhibition of novel benzophenone-benzimidazole analogs. Life Sci (2013) 0.75
Synthesis and evaluation of 2,5-di(4-aryloylaryloxymethyl)-1,3,4-oxadiazoles as anti-cancer agents. Eur J Med Chem (2013) 0.75
Synthesis and evaluation of in vitro antimicrobial activity of novel 2-[2-(aroyl)aroyloxy]methyl-1,3,4-oxadiazoles. Bioorg Khim (2015) 0.75